{
    "symbol": "ERYP",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-22 10:24:03",
    "content": " The second priority for the company and of the remaining 45-ish 40-45 people we have kept a core team in our R&D programs so the focusing on the second priority our preclinical activities, especially on the vesicles, the extracellular vesicles, it's the exosome like, but now derived from red cells, where we held, where we see a lot of promise for immuneoncology applications, and potentially also for RNA and or other non-viral gene delivery. As already noted, in our previous call for Q2 results, the financial results for the first nine months of '22 confirmed a significant and accelerated decrease in operating expenses and cash utilization in connection with the completion and closure of multiple clinical development activities and also the debt restructuring of the company. As a result, the net loss for the first nine months of '22 was \u00e2\u0082\u00ac6.2 million, which was a \u00e2\u0082\u00ac35.4 million improvements over the same period of last year, reflecting the \u00e2\u0082\u00ac24.4 million net gain on the sale of the Princeton facility and the sharp decrease in operating expenses that show an accelerated decrease of \u00e2\u0082\u00ac15.5 million, that's minus 33% year-over-year, it was minus 19% at the end of June. The \u00e2\u0082\u00ac13.6 million net increase in cash position during the first nine months of '22 was the result of the net cash of \u00e2\u0082\u00ac37.6 million received from the sale of the Princeton facility; also a \u00e2\u0082\u00ac27.4 million cash utilization in operating and investing activities, of course, excluding the sale of the Princeton facility, and a \u00e2\u0082\u00ac1.6 million generated in net financing activities."
}